GT Biopharma, Inc. (GTBP)
NASDAQ: GTBP · IEX Real-Time Price · USD
2.820
-0.170 (-5.69%)
Jun 20, 2024, 1:17 PM EDT - Market open

GT Biopharma Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Year
Current20232022202120202019 2018 - 2014
Market Capitalization
6112993335
Upgrade
Market Cap Growth
--63.37%-69.08%181.07%507.58%-83.27%
Upgrade
Enterprise Value
-4-312615419
Upgrade
PE Ratio
-0.63-1.39-1.38-1.61-1.17-0.14
Upgrade
PB Ratio
1.151.412.464.26-1.13-0.28
Upgrade
P/FCF Ratio
-0.61-1.19-1.90-5.98-4.57-1.58
Upgrade
P/OCF Ratio
-0.61-1.19-1.90-5.98-4.57-1.49
Upgrade
EV/EBITDA Ratio
0.380.45-0.60-1.07-2.14-0.51
Upgrade
EV/EBIT Ratio
0.380.45-0.60-1.07-2.14-0.51
Upgrade
EV/FCF Ratio
0.360.38-0.82-3.93-7.47-5.43
Upgrade
Debt / Equity Ratio
0.010.010.010.00-0.89-0.70
Upgrade
Debt / EBITDA Ratio
0.00-0.01-0.010.00-1.04-0.37
Upgrade
Debt / FCF Ratio
0.00-0.01-0.010.00-3.63-3.86
Upgrade
Quick Ratio
2.132.113.343.120.150.00
Upgrade
Current Ratio
2.152.123.353.140.160.01
Upgrade
Interest Coverage
-9635.00-34.67-2609.50-79.80-8.42-17.16
Upgrade
Return on Equity (ROE)
-111.50%-71.80%-137.10%-202.50%105.70%862.30%
Upgrade
Return on Assets (ROA)
-66.10%-44.40%-93.40%-171.70%-1426.20%-296.60%
Upgrade
Return on Capital (ROIC)
-243.39%-180.20%-178.51%-262.13%218.26%277.64%
Upgrade
Earnings Yield
-157.88%-71.93%-72.42%-62.19%-85.27%-707.56%
Upgrade
FCF Yield
-165.63%-83.81%-52.77%-16.73%-21.88%-63.33%
Upgrade
Buyback Yield / Dilution
-27.50%-26.87%-13.19%-542.06%-29.59%-14.50%
Upgrade
Total Shareholder Return
-27.50%-26.87%-13.19%-542.06%-29.59%-14.50%
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).